logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2008 or most recent year available [see all tables in this series...]

Part (i) All clients by country and primary drug and type of treatment unit

CountryAmphetaminesMDMA and other derivatives
OutpatientInpatientOutpatientInpatient
Belgium(1)2831893614
Bulgaria26600
Czech Republic861128372
Denmark37539353
Germany(2)0000
Estonia11000
Ireland2947718
Greece0230
Spain(3)42201820
France10611863
Italy11701160
Cyprus1010
Latvia(4)011206
Lithuania(2)0000
Luxembourg1081
Hungary20327260
Malta(5)00190
Netherlands(6)6060770
Austria5117214
Poland0000
Portugal(7)
Romania23125
Slovenia0020
Slovakia19820511
Finland22017504
Sweden53881275
United Kingdom4274778532
Croatia652436
Turkey01050
Norway

Notes:

 (1) Last data available refer to 2005.   

 (2) Only aggregated data for stimulants (other than cocaine) are available.   

 (3) Last data available refer to 2007.   

 (4) Data for overall number of clients are reported only for inpatient centres.   

 (5) Last data available refer to 2006.   

 (6) Data for outpatient centres refer to outpatient centres, inpatient centres and low-threshold agencies (aggregated data). 

 (7) Portugal has reported 1 new clients (Amphetamines) and 10 new clients (MDMA) in outpatient centres. 

 The number of treatment clients in each country is listed in Table TDI-7

 See also 'General notes for interpreting data’ on the Explanatory notes and help page

Sources:

 Reitox national reports 2009 — TDI. See Table TDI-0 for details on sources. 

(see the help page for information about formats etc.)

Page last updated: Wednesday, 14 July 2010